PDCD1 and neoplasm: As expected, the combined treatment with SR‐1664 and anti‐PD‐1 significantly suppressed tumor growth, and markedly extended overall survival in the TNBC mouse model, compared with the individual treatment with SR‐1664 or anti‐PD‐1 (Figure 6J,K).